Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company, focused on investing in early-stage, preclinical life science companies and therapeutic platforms that align with and complement Takeda's core R&D pipeline.
About Takeda Ventures
Takeda Ventures is the corporate venture arm of Takeda Pharmaceutical Company, one of the largest global pharmaceutical companies, investing in early-stage biotech and life sciences companies with strategic relevance to Takeda’s therapeutic priorities including oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The fund operates with a strategic mandate, meaning investments are evaluated for both financial return and potential alignment with Takeda’s R&D and commercial strategy. Check sizes typically begin in the low single-digit millions at initial commitment and can extend to larger commitments in subsequent rounds, with reserves attached. The natural fit is a biotech or life sciences company with credible scientific founders, a clear development pathway in one of Takeda’s strategic therapeutic areas, and openness to a strategic relationship that could include licensing, collaboration, or eventual acquisition discussions. AI-native drug discovery platforms can engage if the platform is anchored by specific assets in Takeda’s strategic areas; pure software theses without a therapeutic asset will not fit. Digital health, devices, and provider enterprise software are out of scope. Founders should expect rigorous scientific and strategic diligence with input from Takeda’s R&D and business development teams, and a partnership orientation that goes beyond financial capital. The best entry path is a warm introduction from a portfolio CEO, a biotech banker, an academic advisor with Takeda relationships, or a business development contact at Takeda itself. Direct outreach via the website is also a credible path with a strong scientific package.
Founder reviews
Other portfolio companies
Companies in Takeda Ventures's portfolio not currently in our directory.
- Integra Therapeutics · 2025
- Be Biopharma · 2024
- Asceneuron · 2024
- Harness Therapeutics · 2025
- EvolveImmune Therapeutics · 2024
- Larkspur Biosciences
- hC Bioscience
- Egle Therapeutics
- Oak Hill Bio
- Code Biotherapeutics · 2022
- Fate Therapeutics · 2011
Team
Pitch / review this investor
Have you raised from Takeda Ventures? Founders only — share your honest experience (anonymous OK, moderated before publishing).